Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a relatively new and promising class of antidiabetic agents for the management of type 2 diabetes mellitus. Recently, Glenmark has introduced a novel SGLT2 inhibitor called Remogliflozin that has been broadly researched across countries and is supported by 26 clinical studie s, including more than 2500 patients .
Glenmark invites you for an interactive webinar on 7 th July 2019 from 11:30 am onwards. Program Agenda We invite you to submit your questions which will be answered by the speakers at the end of the session.
